Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary – Strides Pharma Science Limited** Strides Pharma faces its most acute financial exposure through a **10/10 compliance risk rating**, with estimated remediation costs of ₹4–13 crore, primarily driven by unclear Extended Producer Responsibility (EPR) applicability and incomplete emissions disclosure under SEBI BRSR Core Expansion mandates. The pharmaceutical sector's chemical processing operations create structural GHG and water intensity risks (both 5.0/10), yet the company reports zero Scope 1 and 2 emissions—a significant reporting gap that exposes it to potential SEBI enforcement action and delisting risk if not resolved. With ₹2,185.6 crore in revenue and an EPR exposure score of 6.5/10, failure to establish baseline emissions and clarify EPR obligations within the next regulatory cycle could trigger penalties and reputational damage. Immediate priority: complete Scope 1/2 quantification, confirm EPR applicability, and implement documented compliance controls to mitigate enforcement risk under SEBI BRSR Core Expansion requirements.
Source: Strides Pharma Science Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.